At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
PF-05082566 +1 moredrug
Likely dose
PF-05082566 0.45 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1B STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
In Brief
A Phase 1 clinical trial evaluating PF-05082566 and MK-3475 for Advanced Solid Tumors. Completed, enrolled 23 participants across 9 sites.
Detailed Summary
This is a safety, pharmacokinetic and pharmacodynamic study designed to estimate the maximum tolerated dose (MTD), and determine the Recommended Phase 2 Dose (RP2D) of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in combination with MK-3475, a PD-1 inhibitor in patients with solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartAug 2014
Primary CompletionFeb 2017
TodayJul 2026
First PostedJul 2, 2014
Enrollment StartAug 1, 2014
Primary CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 12 years ago
Interventions
PF-05082566drug
Starting dose of 0.45 mg/kg q3wks IV, dose escalation
MK-3475drug
2 mg/kg q3wks, IV